Article Figures & Tables
Figures
- Figure 1:
Use of multiple-marker screening (MMS) among all singleton pregnancies with an expected date of delivery between July 1, 2012, and Mar. 31, 2016, in Ontario, by census division. Note: LHIN = Local Health Integration Network.
- Figure 2:
Use of cell-free fetal DNA (cffDNA) screening among singleton pregnancies with an expected date of delivery between July 1, 2014, and Mar. 31, 2016, that had a positive result of multiple-marker screening (MMS), by census division. Note: LHIN = Local Health Integration Network.
- Figure 3:
Prenatal screening pathways before and after cell-free fetal DNA (cffDNA) screening was funded. Women who did not have follow-up testing following a positive result of multiple-marker screening are not shown.
- Figure 4:
Rates of uptake of cell-free fetal DNA (cffDNA) screening and prenatal diagnostic testing among all singleton pregnancies with an expected date of delivery between July 2012 and March 2016. Note: CVS = chorionic villous sampling.
- Figure 5:
Rates of uptake of cell-free fetal DNA (cffDNA) screening and prenatal diagnostic testing among singleton pregnancies with an expected date of delivery between July 2012 and March 2016 that had a positive result of multiple-marker screening. Note: CVS = chorionic villous sampling.
Tables
- Table 1:
Use of cell-free fetal DNA screening and prenatal diagnostic testing in singleton pregnancies by level of risk for trisomy 21 based on multiple-marker screening
Multiple-marker screening risk for trisomy 21 Before cffDNA screening funded*; rate of uptake, % After cffDNA screening funded†; rate of uptake, % cffDNA screening Prenatal diagnostic testing cffDNA screening or prenatal diagnostic testing cffDNA screening Prenatal diagnostic testing cffDNA screening or prenatal diagnostic testing ≥ 1:10 4.0 67.5 70.2 30.5 54.1 76.1 1:11–1:50 6.1 63.1 67.8 44.3 40.5 78.8 1:51–1:100 8.0 55.9 62.6 51.1 29.2 77.3 1:101–1:200 6.4 50.9 56.3 55.1 23.5 76.3 1:201–1:350 3.1 13.1 15.9 25.2 6.0 29.9 1:351–1:500 1.4 6.4 7.5 12.5 2.3 14.6 1:501–1:1000 1.1 4.1 5.2 9.3 1.6 10.6 1:1000–1:5000 0.6 2.0 2.6 5.3 1.0 6.2 < 1:5000 0.2 0.7 0.9 2.0 0.5 2.4 All risk groups‡ 0.6 3.3 3.8 5.0 1.9 6.6
In this issue
Article tools
